logo
Book a meeting
CaraVan Biologix

Cara Van Biologix

Biotechnology, 1967 E Beltline Ave Ne, Princeton, New Jersey, 49525, United States, 1-10 Employees

caravanbio.com

  • LinkedIn

phone no Phone Number: 19********

Who is CARAVAN BIOLOGIX

CaraVan Biologix is a biotechnology company focused on expanding the life-saving benefits of CAR-T cell therapeutics to the broader cancer patient population by addressing their limitatio...

Read More

lock icon Get Full Access
map
  • 1967 E Beltline Ave Ne, Princeton , New Jersey, 49525, United States Headquarters: 1967 E Beltline Ave Ne, Princeton , New Jersey, 49525, United States
  • 2020 Date Founded: 2020
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

checked-icon Does something look wrong? Fix it. | View contact records from CARAVAN BIOLOGIX

CaraVan Biologix Org Chart and Mapping

Employees
Rob Simmons

Rob Simmons

Shareholder

Christineh Sarkissian

Christineh Sarkissian

Science and Business Advisor

See Full Org Chart arrow
email-formate-icon
View Email Formats for CaraVan Biologix
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding CaraVan Biologix

Answer: CaraVan Biologix's headquarters are located at 1967 E Beltline Ave Ne, Princeton, New Jersey, 49525, United States

Answer: CaraVan Biologix's phone number is 19********

Answer: CaraVan Biologix's official website is https://caravanbio.com

Answer: CaraVan Biologix's revenue is Under $1 Million

Answer: CaraVan Biologix has 1-10 employees

Answer: CaraVan Biologix is in Biotechnology

Answer: CaraVan Biologix contact info: Phone number: 19******** Website: https://caravanbio.com

Answer: CaraVan Biologix is a biotechnology company focused on expanding the life-saving benefits of CAR-T cell therapeutics to the broader cancer patient population by addressing their limitations. Our underlying and core novel technologies enable the development of allogenic treatments for a spectrum of human diseases, including solid tumors and hard-to-treat cancers. Our therapeutic agents are expected to show superior safety profiles, including a low risk for cytokine release syndrome. Importantly, our technology will greatly reduce the complexities of manufacturing that are associated with whole-cell therapies, thereby minimizing the time, cost, and variability risk to facilitate greater access for patients in need.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access